Sino Biopharmaceutical's (HKG:1177) Tulobuterol Patches obtained marketing approval from the National Medical Products Administration of China, a Friday bourse filing said.
The approval covers the usage of the patches for the relief of symptoms of obstructive airway diseases including dyspnoea caused by bronchial asthma, acute bronchitis, chronic bronchitis, and emphysema.
Compared to other traditional treatments, tulobuterol patch controls asthma symptoms more effectively and is a more convenient and safer solution for the long-term treatment of patients with obstructive airway diseases.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.